Aurinia Pharmaceuticals (AUPH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Aurinia Pharmaceuticals

NasdaqGM•Healthcare•Biotechnology

$16.96+0.83(0.05%)Pre-market

Market Cap

$2.20B

P/E

7.0x

P/S

7.1x

P/B

3.6x

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

How this company scores

ExcellentMetricSide Score: 90/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability25/25

Growth25/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality25/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 7.0x5y range 6.2x – 226.1x

Currently below its 7-quarter median.

P/S · 7.1x5y range 4.0x – 66.6x

Currently near its 20-quarter median.

P/B · 3.6x5y range 1.5x – 9.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Price & Volume

Market Cap $2.20B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $311.51M
Q. Revenue: $83.22M
TTM EBITDA: $179.85M
TTM Op. Income: $150.75M
Q. Op. Income: $46.34M
TTM Net Income: $314.11M
Q. Net Income: $37.41M
EPS: $0.29
Shares Out.: $130.08M

$311.51M in TTM revenue grew 19.8% YoY, reaching $83.22M last quarter. TTM EBITDA of $179.85M and TTM operating income of $150.75M show growth is flowing through to the bottom line. TTM net income of $314.11M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 92.1%
EBITDA Margin: 61.5%
Op. Margin: 55.7%
Net Margin: 45.0%

Op. margin of 55.7% is up 27.0% YoY — cost efficiency is improving. Net margin at 45.0% and gross margin of 92.1% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 4 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 7.0x
P/S Ratio: 7.1x
P/B Ratio: 3.6x

At 7.0x P/E, the stock trades below typical market levels. P/S of 7.1x and P/B of 3.6x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is down 63% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $792.26M
Cash: $179.73M
Long-Term Debt: N/A
Book Value: $614.86M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $52.57M
TTM Free Cash Flow: $175.07M
FCF Margin: 56.2%
FCF / Net Income: 0.6

TTM FCF of $175.07M on $52.57M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.